Envoy Medical, Inc. (COCH) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Envoy Medical, Inc. is a hearing health company focused on fully implanted hearing devices. The reporting period covers the three and six months ended June 30, 2025. The Company's primary commercial product is the Esteem Fully Implanted Active Middle Ear Implant (FI-AMEI), which generates minimal revenue. The Company is currently in the clinical trial phase for its lead product candidate, the Acclaim Cochlear Implant (Acclaim CI), which received FDA Breakthrough Device Designation in 2019. The Company is classified as a Smaller Reporting Company and an Emerging Growth Company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Revenues | $78 | $68 | $124 | $127 |
| Operating Loss | $(5,070) | $(4,852) | $(10,177) | $(9,735) |
| Net Loss | $(5,690) | $(3,947) | $(10,688) | $(10,217) |
| Net Loss Attributable to Common Stockholders | $(6,942) | $(5,312) | $(13,178) | $(12,947) |
| Cash and Cash Equivalents (End of Period) | $5,287 | $1,746 | $5,287 | $1,746 |
| Total Debt (Related Party Term Loans) | $27,932 | $18,716 | $27,932 | $18,716 |
| Accumulated Deficit | $(297,912) | $(270,203) | $(297,912) | $(270,203) |
Liquidity: As of June 30, 2025, the Company held $5.3 million in cash. Management expects to have sufficient funds for operations through September 2025 without additional funding, though they anticipate raising capital via the Forward Purchase Agreement or At-The-Market (ATM) offering to extend this runway.
Material Changes vs. Prior Period
- Revenue: Net revenues increased slightly by $10,000 (14.7%) in Q2 2025 compared to Q2 2024, remaining nominal. YTD revenues decreased by $3,000.
- Operating Expenses: General and Administrative (G&A) expenses increased significantly by $481,000 (30.3%) in Q2 2025, primarily driven by a $300,000 severance accrual for the former CFO. Research and Development (R&D) expenses decreased by $106,000 (4.1%) as the company transitioned from development to clinical trials.
- Interest Expense: Related party interest expense surged by $492,000 (372.7%) in Q2 2025 due to additional term loan issuances during the period.
- Debt Position: Total term loans payable (related party) increased from $18.7 million at year-end 2024 to $27.9 million at June 30, 2025, following new draws in March and June 2025.
- Warrant Liabilities: The Company recognized a gain of $458,000 YTD 2025 from the change in fair value of forward purchase agreement warrant liabilities, compared to a loss of $18,000 in the prior year period.
Outlook, Risks, and Contingencies
- Clinical Progress: The Acclaim CI pivotal clinical trial (IDE) was granted by the FDA in October 2024. All 10 patients in the first stage were implanted by mid-April 2025 and activated. The Company targets expansion to the second stage (total 56 patients) in Q4 2025 or Q1 2026, with FDA PMA approval anticipated in H2 2027 or H1 2028.
- Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern due to recurring losses and the need for additional financing. Management believes existing cash and future capital raises will fund operations for at least one year.
- Legal Proceedings: The Company is defending a lawsuit filed by Atlas Merchant Capital SPAC Fund I LP alleging damages of approximately $9.4 million related to share redemption restrictions during the SPAC merger. The Company believes the claim is meritless.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses including insufficient accounting personnel, lack of formal risk assessment, and ineffective IT general controls.
- Subsequent Events: On July 28, 2025, the Company amended its Shortfall Warrants to lower the exercise price floor to $1.50.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise, as management projects funds may only last through September 2025 without additional financing.
- Debt Covenants: Review the terms of the related party term loans (GAT Funding), specifically the net tangible asset covenants that trigger additional funding requirements.
- Clinical Trial Milestones: Monitor the activation of the second stage of the Acclaim CI clinical trial and the timeline for FDA PMA submission.
- Internal Control Remediation: Assess the progress of remediation plans for the identified material weaknesses in internal controls over financial reporting.
- Legal Exposure: Track the status of the Atlas Merchant Capital litigation and potential indemnification obligations.